Liver cells are placed under a microscope for study at the CRISPR Therapeutics office in Boston (Amanda Sabga for Endpoints News)
Gene edit­ing's search for a 'holy grail' has led to an ex­plo­sion of tools, but few cures
John Finn still re­mem­bers the twinge of jeal­ousy when he heard some­one else had in­vent­ed a long-sought form of gene edit­ing, one that might fi­nal­ly …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Catal­ent hand­ed two Form 483s, in­clud­ing for Sarep­ta gene ther­a­py site
Mod­els are out, mol­e­cules are in as AI star­tups sprint to clin­ic
Berke­ley start­up rais­es 06.5M for all RNA 'jump­ing gene' ther­a­pies
Fed­er­al judge blocks 340B drug pric­ing pi­lot ahead of Jan. 1 ef­fec­tive date
Ul­tragenyx, Mereo crash on late-stage bone dis­ease fail­ure
Nido Bio to wind down af­ter un­der­whelm­ing Phase 2 da­ta
Gen­mab ends de­vel­op­ment of Phase 3 lung can­cer as­set that BioN­Tech ditched ear­li­er
ASK Pharm makes Chi­na rights deal; Uni­cy­cive re­sub­mits kid­ney drug af­ter CRL
The End­points win­ners and losers list: Who was up and who was down in 2025
Bioscience & Technology Business Center